Cost-effectiveness analysis of combining lenalidomide with R-CHOP for treating diffuse large B-cell lymphoma in China
In the Chinese healthcare system, R2-CHOP is a cost-effective approach for DLBCL compared to R-CHOP, but the costs of lenalidomide and rituximab warrant attention.
Authors
- Rongqi Li (ORCID: https://orcid.org/0000-0002-0613-8751)
- Chuang Chen (ORCID: https://orcid.org/0000-0001-5367-4349)
- Tao Zhou (ORCID: https://orcid.org/0000-0001-6222-2053)
- Ziye Zhou (ORCID: https://orcid.org/0000-0003-0294-7399)
- Yizhang Chen (ORCID: https://orcid.org/0000-0003-3873-4352)
- Zhongjiang Ye
- Xiuhua Zhang
- Jianhui Yang (ORCID: https://orcid.org/0000-0002-6766-2186)
- Jing Fu (ORCID: https://orcid.org/0000-0002-0464-0916)
- Yuhan Zeng
- Shouming Qin (ORCID: https://orcid.org/0000-0002-7411-0101)
- Haige Ye (ORCID: https://orcid.org/0000-0002-6329-1322)
- Danna Jiang
Institutions
- Wenzhou Medical University (CN)
- First Affiliated Hospital of Wenzhou Medical University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2024-12-16
- DOI
- https://doi.org/10.3389/fphar.2024.1412743
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00